# First Line Weekly Chemo/Immunotherapy for Metastatic Head/Neck Squamous Cell Carcinoma Patients

> **NCT04858269** · PHASE2 · RECRUITING · sponsor: **Wake Forest University Health Sciences** · enrollment: 32 (estimated)

## Conditions studied

- Head Neck Cancer
- Metastatic Squamous Cell Carcinoma
- Oral Cavity Squamous Cell Carcinoma
- Oropharynx Squamous Cell Carcinoma
- Hypopharynx Squamous Cell Carcinoma
- Larynx Squamous Cell Carcinoma

## Interventions

- **DRUG:** Pembrolizumab
- **DRUG:** Carboplatin
- **DRUG:** Paclitaxel

## Key facts

- **NCT ID:** NCT04858269
- **Lead sponsor:** Wake Forest University Health Sciences
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2021-05-27
- **Primary completion:** 2026-06
- **Final completion:** 2028-08
- **Target enrollment:** 32 (ESTIMATED)
- **Last updated:** 2026-03-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04858269

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04858269, "First Line Weekly Chemo/Immunotherapy for Metastatic Head/Neck Squamous Cell Carcinoma Patients". Retrieved via AI Analytics 2026-06-11 from https://api.ai-analytics.org/clinical/NCT04858269. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*